Redmile Group, LLC (CIK 1425738) reported 11 SEC Form 4 insider transactions across 3 companies over the past 18 months (most recent 2026-04-22). Recent activity: Sell FATE (9.0M shares), Buy FATE (9.0M shares), Sell ADCT (196,229 shares), Sell ADCT (188,407 shares), Sell ADCT (169,265 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-22 | FATE THERAPEUTICS INC (FATE) | Director | Sell | 9.0M | $0 |
| 2026-04-22 | FATE THERAPEUTICS INC (FATE) | Director | Buy | 9.0M | $0 |
| 2026-04-02 | ADC Therapeutics SA (ADCT) | Insider | Sell | 196,229 | $736,251 |
| 2026-04-02 | ADC Therapeutics SA (ADCT) | Insider | Sell | 188,407 | $706,903 |
| 2026-04-02 | ADC Therapeutics SA (ADCT) | Insider | Sell | 169,265 | $643,038 |
| 2026-04-02 | ADC Therapeutics SA (ADCT) | Insider | Sell | 162,517 | $617,402 |
| 2026-04-02 | ADC Therapeutics SA (ADCT) | Insider | Sell | 2.6M | $8.6M |
| 2026-04-02 | ADC Therapeutics SA (ADCT) | Insider | Sell | 2.5M | $8.3M |
| 2025-08-15 | IGM Biosciences, Inc. (IGMS) | Director | Sell | 3.0M | $0 |
| 2025-07-02 | IGM Biosciences, Inc. (IGMS) | Director | Buy | 828 | $0 |
| 2025-04-02 | IGM Biosciences, Inc. (IGMS) | Director | Buy | 828 | $0 |
Source: SEC Form 4 filings · as of 2026-04-22